Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
68K characters. Original on sec.gov ·
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
(UNLESS INDICATED OTHERWISE, DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)
The following management’s discussion and analysis should be read in conjunction with the management’s discussion and analysis of financial condition and results of operations, liquidity and capital resources included in our 2025 Annual Report on Form 10-K, filed on February 27, 2026 with the SEC (“2025 Form 10-K”).
OVERVIEW
Company Background
We are organized into three reportable operating segments: Taste, Health & Biosciences, and Scent.
Our Taste segment consists of the development and production of a range of flavor compounds and natural taste solutions that are ultimately used by our customers in a diverse variety of products, including savory products (soups, sauces, meat, fish, poultry, snacks, etc.), beverages (juice drinks, carbonated or flavored beverages, spirits, etc.), sweets (bakery products, candy, cereal, chewing gum, etc.), and dairy products (yogurt, ice cream, cheese, etc.). Taste also includes value-added spices and seasoning ingredients for meat, food service, convenience, alternative protein and culinary products.
Our Health & Biosciences segment consists of the development and production of an advanced biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for food and non-food applications. Among many other applications, our portfolio includes cultures for use in fermented foods such as yogurt, cheese and fermented beverages, probiotic strains, household detergents, animal feed, ethanol production and brewing. Health & Biosciences is comprised of Health, Food Biosciences, Home & Personal Care, Animal Nutrition and Grain Processing.
Our Scent segment creates fragrance compounds and fragrance ingredients that are integral elements in the world’s finest perfumes and best-known household and personal care products. Consumer insights, science and creativity are at the heart of our Scent business, along with our unique portfolio of natural and synthetic ingredients, global footprint, innovative technologies and know-how, and customer intimacy. The Scent segment is comprised of Fragrance Compounds and Fragrance Ingredients.
On May 29, 2026, we announced that we entered into a definitive agreement to divest our Food Ingredients disposal group. We determined that the held for sale and discontinued operations criteria have been met during the second quarter of 2026 and the Company has classified the results of operations of its Food Ingredients disposal group, as well as the results of the SCL disposal group, as discontinued operations for all periods presented. Our Food Ingredients disposal group consists of a diversified portfolio across natural, artificial and plant-based specialty food ingredients that provide functional properties solutions for food and beverage products, as well as specialty soy protein with value-added formulations, emulsifiers and sweeteners. The transaction is expected to close in the second quarter of 2027, subject to customary closing conditions and receipt of regulatory approvals.
We completed the divestiture of our Pharma Solutions disposal group, which included certain adjacent businesses, on May 1, 2025 and we divested our Nitrocellulose business, which was within our Pharma Solutions segment, on May 9, 2025. Our former Pharma Solutions segment produced, among other things, a vast portfolio of cellulosics and seaweed-based pharmaceutical excipients, used in prescription and over-the-counter pharmaceuticals and dietary supplements.
Financial Performance Overview of Continuing Operations
Sales
Sales in the third quarter of 2026 increased $73 million, or 4% on a reported basis, to $1.942 billion compared to $1.869 billion in the 2025 period. On a comparable currency neutral basis, sales in the third quarter of 2026 increased 5% compared to the 2025 period. The increase was primarily driven by consolidated volume growth of 5%, with volume growth across all segments. The impact of exchange rate variations on net sales for the third quarter of 2026 was flat. The effect of exchange rates can vary by business and region, depending upon the mix of sales priced in U.S. dollars as compared to other currencies. Comparable portfolio results exclude divestiture impacts of approximately $6 million from the sale of the CitraSource business and Rene Laurent business in France.
Gross Profit
Gross profit in the third quarter of 2026 increased $26 million, or 3%, to $825 million (42.5% of sales) compared to $799 million (42.8% of sales) in the 2025 period. The increase in gross profit was primarily driven by consolidated volume growth of 5%, with volume growth across all segments, and the benefit of tariff refunds received and recognized during the quarter of $7 million, partially offset by the impact of divestitures of $5 million.
RESULTS OF CONTINUING OPERATIONS
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| (DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS) | 2026 | 2025 | Change | 2026 | 2025 | Change | |||||||||||||||||||||||||||||
| Net sales | $ | 1,942 | $ | 1,869 | 4 | % | $ | 5,802 | $ | 5,838 | (1) | % | |||||||||||||||||||||||
| Cost of sales | 1,117 | 1,070 | 4 | % | 3,295 | 3,363 | (2) | % | |||||||||||||||||||||||||||
| Gross profit | 825 | 799 | 3 | % | 2,507 | 2,475 | 1 | % | |||||||||||||||||||||||||||
| Research and development (R&D) expenses | 170 | 162 | 5 | % | 494 | 487 | 1 | % | |||||||||||||||||||||||||||
| Selling and administrative (S&A) expenses | 387 | 348 | 11 | % | 1,158 | 1,147 | 1 | % | |||||||||||||||||||||||||||
| Amortization of acquisition-related intangibles | 78 | 84 | (7) | % | 244 | 246 | (1) | % | |||||||||||||||||||||||||||
| Impairment of goodwill | 23 | — | NMF | 23 | 34 | NMF | |||||||||||||||||||||||||||||
| Restructuring and other charges | 5 | 14 | (64) | % | 15 | 49 | (69) | % | |||||||||||||||||||||||||||
| Losses on sale of assets | 2 | — | NMF | 2 | 1 | NMF | |||||||||||||||||||||||||||||
| Operating profit | 160 | 191 | (16) | % | 571 | 511 | 12 | % | |||||||||||||||||||||||||||
| Interest expense | 46 | 48 | (4) | % | 136 | 180 | (24) | % | |||||||||||||||||||||||||||
| Gain on extinguishment of debt | — | — | NMF | — | (488) | NMF | |||||||||||||||||||||||||||||
| (Gains) losses on business disposals | (2) | — | NMF | (1) | 111 | (101) | % | ||||||||||||||||||||||||||||
| Loss on assets classified as held for sale | 236 | — | NMF | 263 | — | NMF | |||||||||||||||||||||||||||||
| Other expense, net | 14 | 13 | 8 | % | 47 | 52 | (10) | % | |||||||||||||||||||||||||||
| (Loss) Income from continuing operations before taxes | (134) | 130 | (203) | % | 126 | 656 | (81) | % | |||||||||||||||||||||||||||
| (Benefit) Provision for income taxes | (7) | 31 | (123) | % | 65 | (61) | (207) | % | |||||||||||||||||||||||||||
| Net (loss) income from continuing operations | $ | (127) | $ | 99 | (228) | % | $ | 61 | $ | 717 | (91) | % | |||||||||||||||||||||||
| Income (loss) from discontinued operations before tax | 99 | (74) | (234) | % | 143 | (1,090) | (113) | % | |||||||||||||||||||||||||||
| Provision (benefit) for income taxes from discontinued operations | 27 | (16) | (269) | % | 38 | 4 | NMF | ||||||||||||||||||||||||||||
| Net income (loss) from discontinued operations | 72 | (58) | (224) | % | 105 | (1,094) | (110) | % | |||||||||||||||||||||||||||
| Net (loss) income | (55) | 41 | (234) | % | 166 | (377) | (144) | % | |||||||||||||||||||||||||||
| Net income attributable to non-controlling interests from continuing operations | — | — | NMF | 1 | 1 | — | % | ||||||||||||||||||||||||||||
| Net income attributable to non-controlling interests from discontinued operations | — | 1 | (100) | % | 1 | 1 | — | % | |||||||||||||||||||||||||||
| Net (loss) income attributable to IFF shareholders | $ | (55) | $ | 40 | (238) | % | $ | 164 | $ | (379) | (143) | % | |||||||||||||||||||||||
| (Loss) Income per share - basic | |||||||||||||||||||||||||||||||||||
| Continuing operations | $ | (0.50) | $ | 0.39 | (230) | % | $ | 0.24 | $ | 2.81 | (92) | % | |||||||||||||||||||||||
| Discontinued operations | 0.28 | (0.23) | (224) | % | 0.41 | (4.29) | (110) | % | |||||||||||||||||||||||||||
| Net (loss) income per share - basic | $ | (0.22) | $ | 0.16 | (239) | % | $ | 0.65 | $ | (1.48) | (144) | % | |||||||||||||||||||||||
| (Loss) Income per share - diluted | |||||||||||||||||||||||||||||||||||
| Continuing operations | $ | (0.50) | $ | 0.39 | (230) | % | $ | 0.23 | $ | 2.80 | (92) | % | |||||||||||||||||||||||
| Discontinued operations | 0.28 | (0.23) | (224) | % | 0.41 | (4.28) | (110) | % | |||||||||||||||||||||||||||
| Net (loss) income per share - diluted | $ | (0.22) | $ | 0.16 | (240) | % | $ | 0.64 | $ | (1.48) | (143) | % | |||||||||||||||||||||||
| Gross margin | 42.5 | % | 42.8 | % | (30) | bps | 43.2 | % | 42.4 | % | 80 | bps | |||||||||||||||||||||||
| R&D as a percentage of sales | 8.8 | % | 8.7 | % | 10 | bps | 8.5 | % | 8.3 | % | 20 | bps | |||||||||||||||||||||||
| S&A as a percentage of sales | 19.9 | % | 18.6 | % | 130 | bps | 20.0 | % | 19.6 | % | 40 | bps | |||||||||||||||||||||||
| Operating margin | 8.2 | % | 10.2 | % | (200) | bps | 9.8 | % | 8.8 | % | 100 | bps | |||||||||||||||||||||||
| Effective tax rate | 5.2 | % | 23.8 | % | NMF | 51.6 | % | (9.3) | % | NMF | |||||||||||||||||||||||||
| Segment net sales | |||||||||||||||||||||||||||||||||||
| Taste | $ | 687 | $ | 658 | 4 | % | $ | 2,055 | $ | 1,962 | 5 | % | |||||||||||||||||||||||
| Health & Biosciences | 566 | 559 | 1 | % | 1,742 | 1,638 | 6 | % | |||||||||||||||||||||||||||
| Scent | 689 | 652 | 6 | % | 2,005 | 1,869 | 7 | % | |||||||||||||||||||||||||||
| Pharma Solutions | — | — | NMF | — | 369 | (100) | % | ||||||||||||||||||||||||||||
| Consolidated | $ | 1,942 | $ | 1,869 | 4 | % | $ | 5,802 | $ | 5,838 | (1) | % |
NMF: Not meaningful
Cost of sales includes the cost of materials and manufacturing expenses. R&D expenses include expenses related to the development of new and improved products and technical product support. S&A expenses include expenses necessary to support our commercial activities and administrative expenses supporting our overall operating activities including compliance with governmental regulations.
THIRD QUARTER 2026 IN COMPARISON TO THIRD QUARTER 2025
Sales performance by segment was as follows:
| % Change in Sales - Third Quarter 2026 vs. Third Quarter 2025 | |||||||||||||||||
| Reported | Currency Neutral**(2)** | Comparable Currency Neutral**(1)(2)** | |||||||||||||||
| Taste | 4 | % | 5 | % | 6 | % | |||||||||||
| Health & Biosciences | 1 | % | 1 | % | 1 | % | |||||||||||
| Scent | 6 | % | 6 | % | 6 | % | |||||||||||
| Total | 4 | % | 4 | % | 5 | % |
Comparable currency neutral reported performance by segment was as follows:
| Three Months Ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Net Sales | |||||||||||
| Taste | $ | 691 | $ | 654 | |||||||
| Health & Biosciences | 566 | 559 | |||||||||
| Scent | 691 | 650 | |||||||||
| Impact of Business Divestitures(1) | — | 6 | |||||||||
| Impact of Currency Fluctuations(2) | (6) | — | |||||||||
| Total | $ | 1,942 | $ | 1,869 |
(1)Impact of business divestitures in 2025 includes results of the Rene Laurent business (divested December 1, 2025) and the CitraSource business (divested July 1, 2026).
(2)Currency neutral sales are calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.
Taste
Taste sales in 2026 increased $29 million, or 4% on a reported basis, to $687 million compared to $658 million in the prior year period. On a comparable currency neutral basis, Taste sales increased 6% in 2026 compared to the prior year period, primarily driven by volume increases of 5% across various business units. Exchange rate variations had an unfavorable impact of 1%. Comparable portfolio results exclude the impact of the divestiture of the Rene Laurent business with a sales impact of approximately $4 million.
Health & Biosciences
Health & Biosciences sales in 2026 increased $7 million, or 1% on a reported basis, to $566 million compared to $559 million in the prior year period. On a comparable currency neutral basis, Health & Biosciences sales increased 1% in 2026 compared to the prior year period, primarily driven by volume increases of 2% across various business units. Exchange rate variations remained flat.
Scent
Scent sales in 2026 increased $37 million, or 6% on a reported basis, to $689 million compared to $652 million in the prior year period. On a comparable currency neutral basis, Scent sales increased 6% in 2026 compared to the prior year period, primarily driven by volume increases of 7% across business units. Exchange rate variations remained flat.
Cost of Sales
Cost of sales increased $47 million to $1.117 billion (57.5% of sales) in the third quarter of 2026 compared to $1.070 billion (57.2% of sales) in the third quarter of 2025. The increase in cost of sales was primarily driven by volume increases of 5%.
Research and Development (“R&D”) Expenses
R&D expenses increased $8 million to $170 million (8.8% of sales) in the third quarter of 2026 compared to $162 million (8.7% of sales) in the third quarter of 2025 primarily driven by higher incentive compensation expense.
Selling and Administrative (“S&A”) Expenses
S&A expenses increased $39 million to $387 million (19.9% of sales) in the third quarter of 2026 compared to $348 million (18.6% of sales) in the third quarter of 2025. The increase in S&A expenses was primarily driven by additional regulatory costs of $28 million and higher incentive compensation expense.
Impairment of Goodwill
The Company recognized a $23 million goodwill impairment charge in 2026 related to the Botanicals & Food Enhancements disposal group. See Note 4 for additional information.
Amortization of Acquisition-Related Intangibles
Amortization expenses decreased to $78 million in the third quarter of 2026 compared to $84 million in the third quarter of 2025. The decrease in amortization expense was primarily driven by the intangible assets of the Botanicals & Food Enhancements disposal group and Meat Cultures business being classified as held for sale, and therefore no longer recognizing amortization expense on those intangible assets. See Note 12 for additional information.
Restructuring and Other Charges
Restructuring and other charges decreased to $5 million in the third quarter of 2026 compared to $14 million in the third quarter of 2025. The decrease was driven by lower severance expense. See Note 5 for additional information.
Interest Expense
Interest expense decreased to $46 million in the third quarter of 2026 compared to $48 million in the third quarter of 2025. The decrease in interest expense was due to lower debt outstanding. See Note 14 for additional information.
(Gains) Losses on Business Disposals
The net gain on business disposals was $2 million in the third quarter of 2026. The net gain in 2026 was driven by the post-closing adjustments for the Nitrocellulose divestiture. See Note 4 for additional information.
Loss on Assets Classified as Held for Sale
There was a $236 million loss on assets classified as held for sale in the third quarter of 2026 related to the Botanicals & Food Enhancements disposal group. See Note 4 for additional information.
Other Expense, Net
Other expense, net, increased to $14 million in the third quarter of 2026 compared to $13 million in the third quarter of 2025. See Note 9 for additional information.
Income Taxes
The effective tax rate for the three months ended September 30, 2026 decreased to 5.2% compared to 23.8% for the three months ended September 30, 2025. The year-over-year decrease was primarily driven by a discrete tax benefit resulting from the resolution of a Mexican tax matter as well as a non-deductible goodwill impairment. Additionally, the Company has reviewed the Global Anti-Base Erosion Model Rules (“Pillar Two”) introduced by the Organisation for Economic Cooperation and Development (“OECD”) and has determined that Pillar Two did not have a significant impact on the current period and is not expected to have a significant impact on income tax expense for the fiscal 2026 period.
Segment Adjusted Operating EBITDA Results by Business Unit
The Company uses Segment Adjusted Operating EBITDA for internal reporting and performance measurement purposes. Segment Adjusted Operating EBITDA is defined as Income Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges and certain items that are not related to recurring operations. Our determination of reportable segments was made on the basis of our strategic priorities within each segment and corresponds to the manner in which our Chief Operating Decision Maker reviews and evaluates operating performance to make decisions about resources to be allocated to the segment. In addition to our strategic priorities, segment reporting is also based on differences in the products and services we provide.
Adjusted Operating EBITDA performance by segment was as follows:
| % Change in Adjusted Operating EBITDA - Third Quarter 2026 vs. Third Quarter 2025 | |||||||||||
| Reported | Comparable Currency Neutral Adjusted**(1)(2)(3)** | ||||||||||
| Taste | 4 | % | 7 | % | |||||||
| Health & Biosciences | 1 | % | 2 | % | |||||||
| Scent | 9 | % | 10 | % | |||||||
| Total | 5 | % | 6 | % |
Comparable Currency Neutral Adjusted Operating EBITDA by segment was as follows:
| Three Months Ended September 30, | |||||||||||
| (DOLLARS IN MILLIONS) | 2026 | 2025 | |||||||||
| Segment Adjusted Operating EBITDA from Continuing Operations: | |||||||||||
| Taste | $ | 130 | $ | 122 | |||||||
| Health & Biosciences | 136 | 134 | |||||||||
| Scent | 138 | 125 | |||||||||
| Impact of Business Divestitures(2) | — | 3 | |||||||||
| Impact of Currency Fluctuations(3) | (1) | — | |||||||||
| Total | 403 | 384 | |||||||||
| Depreciation & Amortization | (156) | (151) | |||||||||
| Interest Expense | (46) | (48) | |||||||||
| Other Expense, net | (14) | (13) | |||||||||
| Restructuring and Other Charges | (5) | (14) | |||||||||
| Impairment of Goodwill | (23) | — | |||||||||
| Gains on Business Disposals | 2 | — | |||||||||
| Loss on Assets Classified as Held for Sale | (236) | — | |||||||||
| Divestiture Costs | (10) | (11) | |||||||||
| Strategic Initiative Costs | (9) | (10) | |||||||||
| Regulatory Costs | (34) | (7) | |||||||||
| Other | (6) | — | |||||||||
| Income from continuing operations before taxes | $ | (134) | $ | 130 | |||||||
| Segment Adjusted Operating EBITDA margin: | |||||||||||
| Taste | 18.8 | % | 18.7 | % | |||||||
| Health & Biosciences | 24.0 | % | 24.0 | % | |||||||
| Scent | 20.0 | % | 19.2 | % | |||||||
| Consolidated | 20.8 | % | 20.5 | % |
(1)Refer to Note 7 for a reconciliation of Adjusted Operating EBITDA to Income (Loss) Before Taxes from continuing operations.
(2)Comparable portfolio results for 2025 exclude the impact of divestitures.
(3)Currency neutral amounts are calculated by translating current year transaction amounts at the exchange rates for the corresponding prior year period.
Taste Segment Adjusted Operating EBITDA
Taste Segment Adjusted Operating EBITDA increased $5 million, or 4% on a reported basis, to $128 million in the third quarter of 2026 (18.6% of segment sales) from $123 million (18.7% of segment sales) in the comparable 2025 period. On
a comparable currency neutral basis, Taste Segment Adjusted Operating EBITDA increased 7% in 2026 compared to the prior year period led primarily by volume increases.
Health & Biosciences Segment Adjusted Operating EBITDA
Health & Biosciences Segment Adjusted Operating EBITDA increased $2 million, or 1% on a reported basis, to $136 million in the third quarter of 2026 (24.0% of segment sales) from $134 million in the comparable 2025 period (24.0% of segment sales). On a comparable currency neutral basis, Health & Biosciences Segment Adjusted Operating EBITDA increased 2% in 2026 compared to the prior year period led primarily by volume increases.
Scent Segment Adjusted Operating EBITDA
Scent Segment Adjusted Operating EBITDA increased $12 million, or 9% on a reported basis, to $139 million in the third quarter of 2026 (20.2% of segment sales) from $127 million (19.5% of segment sales) in the comparable 2025 period. On a comparable currency neutral basis, Scent Segment Adjusted Operating EBITDA increased 10% in 2026 compared to the prior year period led primarily by volume increases and the net benefit of tariff refunds of $6 million.
FIRST NINE MONTHS 2026 IN COMPARISON TO FIRST NINE MONTHS 2025
Sales
Sales for the first nine months of 2026 decreased $36 million, or 1% on a reported basis, to $5.802 billion compared to $5.838 billion in the 2025 period. On a comparable currency neutral basis, sales for the first nine months of 2026 increased 4% compared to the 2025 period. Exchange rate variations had a favorable impact on net sales in the first nine months of 2026 of 2%. The effect of exchange rates can vary by business and region, depending upon the mix of sales priced in U.S. dollars as compared to other currencies. Comparable portfolio results exclude the impact of divestitures which was approximately $385 million.
Sales Performance by Segment
| % Change in Sales - First Nine Months 2026 vs. First Nine Months 2025 | |||||||||||||||||
| Reported | Currency Neutral**(2)** | Comparable Currency Neutral**(1)(2)** | |||||||||||||||
| Taste | 5 | % | 3 | % | 4 | % | |||||||||||
| Health & Biosciences | 6 | % | 4 | % | 4 | % | |||||||||||
| Scent | 7 | % | 5 | % | 5 | % | |||||||||||
| Pharma Solutions | -100 | % | -100 | % | — | % | |||||||||||
| Total | -1 | % | -3 | % | 4 | % |
Comparable currency neutral reported performance by segment was as follows:
| Nine Months Ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Net Sales | |||||||||||
| Taste | $ | 2,028 | $ | 1,948 | |||||||
| Health & Biosciences | 1,700 | 1,638 | |||||||||
| Scent | 1,963 | 1,867 | |||||||||
| Impact of Business Divestitures(1) | — | 385 | |||||||||
| Impact of Currency Fluctuations(2) | 111 | — | |||||||||
| Total | $ | 5,802 | $ | 5,838 |
(1)Impact of business divestitures in 2025 includes results of the Rene Laurent business (divested December 1, 2025), the CitraSource business (divested July 1, 2026), and the Pharma Solutions disposal group and Nitrocellulose business (divested May 1, 2025 and May 9, 2025, respectively).
(2)Currency neutral sales are calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.
Taste
Taste sales in 2026 increased $93 million, or 5% on a reported basis, to $2.055 billion compared to $1.962 billion in the prior year period. On a comparable currency neutral basis, Taste sales increased 4% in 2026 compared to the prior year period,
primarily driven by volume increases of 3%. Exchange rate variations had a favorable impact of 2%. Comparable portfolio results exclude the impact of the divestiture of the Rene Laurent business with a sales impact of approximately $14 million.
Health & Biosciences
Health & Biosciences sales in 2026 increased $104 million, or 6% on a reported basis, to $1.742 billion compared to $1.638 billion in the prior year period. On a comparable currency neutral basis, Health & Biosciences sales increased 4% in 2026 compared to the prior year period, primarily driven by volume increases of 4%. Exchange rate variations had a favorable impact of 2%.
Scent
Scent sales in 2026 increased $136 million, or 7% on a reported basis, to $2.005 billion compared to $1.869 billion in the prior year period. On a comparable currency neutral basis, Scent sales increased 5% in 2026 compared to the prior year period, driven by volume increases of 6%. Exchange rate variations had a favorable impact of 2%.
Pharma Solutions
The Company completed the divestiture of the Pharma Solutions disposal group on May 1, 2025, and the Nitrocellulose business on May 9, 2025. Accordingly, there were no Pharma Solutions segment results reported for the nine months ended September 30, 2026.
Cost of sales
Cost of sales decreased $68 million to $3.295 billion (56.8% of sales) in the first nine months of 2026 compared to $3.363 billion (57.6% of sales) in the 2025 period. The decrease in cost of sales was primarily driven by the impact of divestitures of approximately $252 million and the benefit of tariff refunds recognized during the period of $33 million, partially offset by volume increases of 4%.
Research and Development (“R&D”) Expenses
R&D expenses increased $7 million to $494 million (8.5% of sales) in the first nine months of 2026 compared to $487 million (8.3% of sales) in the 2025 period. The increase in R&D expenses was primarily driven by higher incentive compensation expense.
Selling and Administrative (“S&A”) Expenses
S&A expenses increased $11 million to $1.158 billion (20.0% of sales) in the first nine months of 2026 compared to $1.147 billion (19.6% of sales) in the 2025 period. The increase in S&A expenses was primarily driven by increased regulatory costs of $45 million and higher incentive compensation expense of $44 million, partially offset by lower divestiture costs of $63 million.
Amortization of Acquisition-Related Intangibles
Amortization expenses decreased to $244 million in the first nine months of 2026 compared to $246 million in the 2025 period. The decrease in amortization expense was primarily driven by the intangible assets of the Botanicals & Food Enhancements disposal group and Meat Cultures business being classified as “held for sale,” and therefore no longer recognizing amortization expense on those intangible assets, partially offset by the impact of foreign currency exchange rates. See Note 12 for additional information.
Impairment of Goodwill
The impairment of goodwill decreased to $23 million in the first nine months of 2026 from $34 million in the 2025 period. The 2026 impairment of goodwill was related to the Botanicals & Food Enhancements disposal group. The 2025 impairment of goodwill was attributable to the portion of the Food Ingredients reporting unit that is not included within the Food Ingredients or SCL disposal groups. See Note 4 for additional information.
Restructuring and Other Charges
Restructuring and other charges decreased to $15 million in the first nine months of 2026 compared to $49 million in the 2025 period. The decrease was driven by lower severance costs incurred as part of the IFF Productivity Program in 2026 compared to 2025. See Note 5 for additional information.
Interest Expense
Interest expense decreased to $136 million in the first nine months of 2026 compared to $180 million in the 2025 period. The decrease in interest expense was due to lower debt outstanding. See Note 14 for additional information.
Gain on Extinguishment of Debt
Gain on extinguishment of debt was $488 million in the first nine months of 2025 due to the repurchase of approximately $2.5 billion of notes for approximately $2.0 billion in cash, using the proceeds from the divestitures. See Note 14 for additional information.
(Gains) Losses on Business Disposals
A net gain on business disposals of $1 million was recognized during the first nine months of 2026 compared to a net loss of $111 million during the 2025 period. The net loss in 2025 was primarily driven by the Pharma Solutions disposal group and Nitrocellulose business divestitures. See Note 4 for additional information.
Loss on Assets Classified as Held for Sale
During the first nine months of 2026, the Company recognized losses on assets classified as held for sale of $236 million related to the Botanicals & Food Enhancements disposal group and $27 million related to the CitraSource business. See Note 4 for additional information.
Other Expense, Net
Other expense, net, was $47 million in the first nine months of 2026 compared to $52 million in the 2025 period. The decrease was due to decreased foreign exchange losses, partially offset by lower pension-related benefit in 2026. See Note 9 for additional information.
Income Taxes
The effective tax rate for the nine months ended September 30, 2026 was 51.6% compared to (9.3)% for the nine months ended September 30, 2025. The year-over-year increase was primarily driven by non-deductible regulatory costs and changes in the mix of earnings following business divestitures, as well as tax costs associated with repatriation activities, partially offset by a discrete benefit resulting from the resolution of a Mexican tax matter. For the nine months ended September 30, 2025, benefits were received primarily driven by the entity realignment project and favorable legislative changes impacting U.S. foreign inclusions. These were offset by goodwill impairment and the impact of business divestitures. Additionally, the Company has reviewed the Pillar Two rules introduced by the OECD and has determined that Pillar Two did not have a significant impact on the current period and is not expected to have a significant impact on income tax expense for the fiscal 2026 period.
Segment Adjusted Operating EBITDA Results by Business Unit
The Company uses Segment Adjusted Operating EBITDA for internal reporting and performance measurement purposes. Segment Adjusted Operating EBITDA is defined as Income Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges and certain items that are not related to recurring operations. Our determination of reportable segments was made on the basis of our strategic priorities within each segment and corresponds to the manner in which our Chief Operating Decision Maker reviews and evaluates operating performance to make decisions about resources to be allocated to the segment. In addition to our strategic priorities, segment reporting is also based on differences in the products and services we provide.
Adjusted Operating EBITDA performance by segment was as follows:
| % Change in Adjusted Operating EBITDA - First Nine Months 2026 vs. First Nine Months 2025 | |||||||||||
| Reported | Comparable Currency Neutral Adjusted**(1)(2)(3)** | ||||||||||
| Taste | 9 | % | 11 | % | |||||||
| Health & Biosciences | 8 | % | 6 | % | |||||||
| Scent | 7 | % | 5 | % | |||||||
| Pharma Solutions | -100 | % | — | % | |||||||
| Total | 1 | % | 7 | % |
Comparable Currency Neutral Adjusted Operating EBITDA by segments was as follows:
| Nine Months Ended September 30, | |||||||||||
| (DOLLARS IN MILLIONS) | 2026 | 2025 | |||||||||
| Segment Adjusted Operating EBITDA from Continuing Operations: | |||||||||||
| Taste | $ | 398 | $ | 358 | |||||||
| Health & Biosciences | 413 | 390 | |||||||||
| Scent | 396 | 378 | |||||||||
| Impact of Business Divestitures(2) | — | 101 | |||||||||
| Impact of Currency Fluctuations(3) | 37 | — | |||||||||
| Total | 1,244 | 1,227 | |||||||||
| Depreciation & Amortization | (462) | (439) | |||||||||
| Interest Expense | (136) | (180) | |||||||||
| Other Expense, net | (47) | (52) | |||||||||
| Restructuring and Other Charges | (15) | (49) | |||||||||
| Impairment of Goodwill | (23) | (34) | |||||||||
| Gains (Losses) on Business Disposals | 1 | (111) | |||||||||
| Loss on Assets Classified as Held for Sale | (263) | — | |||||||||
| Divestiture Costs | (25) | (88) | |||||||||
| Strategic Initiative Costs | (27) | (24) | |||||||||
| Gain on Debt Extinguishment | — | 488 | |||||||||
| Regulatory Costs | (115) | (71) | |||||||||
| Entity Realignment Costs | (2) | (5) | |||||||||
| Other | (4) | (6) | |||||||||
| Income from continuing operations before taxes | $ | 126 | $ | 656 | |||||||
| Segment Adjusted Operating EBITDA margin: | |||||||||||
| Taste | 19.6 | % | 18.4 | % | |||||||
| Health & Biosciences | 24.3 | % | 23.8 | % | |||||||
| Scent | 20.2 | % | 20.2 | % | |||||||
| Consolidated | 21.4 | % | 21.0 | % |
(1)Refer to Note 7 for a reconciliation of Adjusted Operating EBITDA to Income (Loss) Before Taxes from continuing operations.
(2)Comparable portfolio results for 2025 exclude the impact of divestitures.
(3)Currency neutral amounts are calculated by translating current year transaction amounts at the exchange rates for the corresponding prior year period.
Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Health & Biosciences, and Scent segments for comparability purposes.
| Nine Months Ended September 30, 2025 | |||||||||||||||||
| Selling & Administrative Expenses | Total EBITDA Impact | ||||||||||||||||
| Taste | $ | 6 | $ | (6) | |||||||||||||
| Health & Biosciences | 6 | (6) | |||||||||||||||
| Scent | 6 | (6) | |||||||||||||||
| Total | $ | 18 | $ | (18) |
Taste Segment Adjusted Operating EBITDA
Taste Segment Adjusted Operating EBITDA increased $35 million, or 9% on a reported basis, to $404 million in the first nine months of 2026 (19.7% of segment sales) from $369 million (18.8% of segment sales) in the comparable 2025 period. On a comparable currency neutral basis, Taste Segment Adjusted Operating EBITDA increased 11% in 2026 compared to the prior year period, primarily driven by volume increases. Comparable portfolio results exclude the impact of the divestiture of the Rene Laurent business with a EBITDA impact of approximately $5 million.
Health & Biosciences Segment Adjusted Operating EBITDA
Health & Biosciences Segment Adjusted Operating EBITDA increased $30 million, or 8% on a reported basis, to $426 million in the first nine months of 2026 (24.5% of segment sales) from $396 million in the comparable 2025 period (24.2% of segment sales). On a comparable currency neutral basis, Health & Biosciences Segment Adjusted Operating EBITDA increased 6% in 2026 compared to the prior year period, primarily driven by volume increases and the $8 million net benefit of tariff refunds.
Scent Segment Adjusted Operating EBITDA
Scent Segment Adjusted Operating EBITDA increased $28 million, or 7% on a reported basis, to $414 million in the first nine months of 2026 (20.6% of segment sales) from $386 million (20.7% of segment sales) in the comparable 2025 period. On a comparable currency neutral basis, Scent Segment Adjusted Operating EBITDA increased 5% in 2026 compared to the prior year period, primarily driven by volume increases and the $9 million net benefit of tariff refunds.
Pharma Solutions Segment Adjusted Operating EBITDA
The Company completed the divestiture of the Pharma Solutions disposal group on May 1, 2025, and the Nitrocellulose business on May 9, 2025. Accordingly, there were no Pharma Solutions segment results reported for the nine months ended September 30, 2026.
Liquidity
Cash and Cash Equivalents
We had cash and cash equivalents of $519 million at September 30, 2026 compared to $590 million on the Consolidated Balance Sheets at December 31, 2025. Of the $519 million balance at September 30, 2026, $5 million was classified as assets held for sale and $242 million was included in current assets from discontinued operations. Of the $590 million balance at December 31, 2025, $243 million was included in current assets from discontinued operations. A portion of this balance was held outside the United States. Cash balances held in foreign jurisdictions are, in most circumstances, available to be repatriated to the United States.
Effective utilization of the cash generated by our international operations is a critical component of our strategy. We regularly repatriate cash from our non-U.S. subsidiaries to fund financial obligations in the U.S. As we repatriate these funds to the U.S., there will be required income taxes payable in certain U.S. states and applicable foreign withholding taxes during the period when such repatriation occurs. Accordingly, as of September 30, 2026, we had a deferred tax liability of approximately $167 million for the effect of repatriating the funds to the U.S., attributable to various non-U.S. subsidiaries. There is no deferred tax liability associated with non-U.S. subsidiaries where we intend to indefinitely reinvest the earnings to fund local operations and/or capital projects.
Cash Flows Provided By Operating Activities
Cash flows provided by operating activities for the nine months ended September 30, 2026 were $820 million, compared to $532 million for the nine months ended September 30, 2025. The increase in cash flows from operating activities during 2026 was primarily driven by the decrease in working capital, largely related to inventories, accounts payables and a smaller incentive compensation payout made in 2026 related to 2025 results compared to the prior year, partially offset by an increase in accounts receivable in the current year.
Cash Flows (Used In) Provided By Investing Activities
Cash flows used in investing activities for the nine months ended September 30, 2026 were $274 million, compared to cash flows provided by investing activities of $2.426 billion in the prior year period. Investing cash outflows used in the current year were primarily driven by $449 million of additions to property, plant and equipment, partially offset by $247 million of net proceeds from the divestiture of the SCL disposal group, the collection of an earnout related to the prior year divestiture of the Pharma Solutions disposal group, and net proceeds from the divestiture of the CitraSource business. Cash flows provided by investing activities during 2025 were primarily comprised of net proceeds of $2.707 billion received in the prior year period from the divestitures of the Pharma Solutions disposal group, the Nitrocellulose business and the Tobacco Flavoring business in North America, partially offset by additions to property, plant and equipment of $406 million.
We have evaluated and re-prioritized our capital projects and expect that capital spending in 2026 will be approximately 5.5% of total company sales (net of potential grants and other reimbursements from government authorities), consistent with capital spending in 2025.
Cash Flows Used In Financing Activities
Cash flows used in financing activities for the nine months ended September 30, 2026 were $609 million, compared to $2.891 billion in the prior year period. The decrease in cash flows used in financing activities was primarily driven by the Company’s prior year purchase for cash of certain of its outstanding series of Senior Notes for an aggregate purchase price, excluding accrued and unpaid interest, of $2.0 billion, as well as $1.0 billion of proceeds from the Delayed Draw Term Loan Facility, which substantially funded the repayment of the €800 million ($912 million) 2026 Euro Notes on September 25, 2026. The decrease was also driven by decreased net commercial paper borrowings of $224 million during the nine months ended September 30, 2026 compared to $370 million in the 2025 period. The decrease was partially offset by $584 million of common stock repurchases under the Company’s share repurchase programs.
We paid dividends totaling $306 million in both the 2026 and 2025 periods. We declared a cash dividend per share of $0.40 in the third quarter of 2026 that was paid on October 9, 2026 to all shareholders of record as of September 18, 2026.
Our capital allocation strategy seeks to maintain investment grade ratings while investing in the business, continuing to pay dividends, repurchasing outstanding shares and repaying debt. We make capital investments in our businesses to support our operational needs and strategic long-term plans. We are committed to maintaining our history of paying a dividend to investors which is determined by our Board of Directors at its discretion based on various factors.
Share Repurchase Authorization
On August 4, 2026, the Company announced that its Board of Directors authorized an enhanced share repurchase authorization with a total value of $2.5 billion; this amount included approximately $400 million remaining on its prior authorization. Under the program, the Board of Directors authorized an accelerated share repurchase (“ASR”) of $500 million.
On August 21, 2026, the Company entered into an ASR agreement with Wells Fargo Bank, National Association to repurchase the Company’s shares under a forward share repurchase transaction. During the three months ended September 30, 2026, the Company received approximately 4.8 million shares related to the ASR Agreement and recorded $500 million to treasury stock for the cost of shares received as well as associated fees and excise tax. On November 3, 2026, upon final settlement of the ASR agreement, the Company received approximately 1 million additional shares.
The remaining unused amount of the share repurchase authorization is expected to be executed following the closing of the Food Ingredients disposal group divestiture, with an expected completion of the program by the end of 2027. The Board will review the share repurchase program periodically and may authorize adjustments of its term and size. The Company plans to fund repurchases from cash provided by operating activities, short-term debt and net cash proceeds provided by the divestiture of the Food Ingredients disposal group.
Factoring Arrangements
We utilize both company-sponsored and customer-sponsored non-recourse receivables factoring programs as part of our working capital and liquidity management strategy. Under these arrangements, we sell the trade receivables to unrelated financial institutions and account for the transactions as sales of receivables. On a total Company basis (including both continuing operations and discontinued operations), during the nine months ended September 30, 2026 and September 30, 2025, we sold approximately $1,162 million and $824 million respectively, of receivables under our own factoring agreements and $305 million and $556 million respectively, of receivables under customer-sponsored factoring agreements. Both company-sponsored and customer-sponsored agreements generated cash proceeds that were reflected in operating cash flows. The Company has $575 million of total capacity under its company-sponsored factoring agreements, of which approximately $294 million is available as of September 30, 2026.
Our participation in these programs accelerates the conversion of trade receivables into cash and provides an additional source of short-term liquidity, resulting in a benefit to operating cash flow for the period. While we do not depend on these arrangements to fund our operations or capital requirements, a material reduction or discontinuation of the programs could temporarily cause an unfavorable impact on operating cash flows because receivables would remain outstanding longer before cash collection. Refer to Note 1 for further information regarding these arrangements.
Capital Resources
Operating cash flow provides the primary source of funds for capital investment needs, dividends paid to shareholders and debt service repayments. We anticipate that cash flows from operations, cash proceeds generated from planned business divestitures and availability under our existing credit facilities will be sufficient to meet our investing and financing needs, including our debt service requirements for the foreseeable future. We regularly assess our capital structure, including both current and long-term debt instruments, as compared to our cash generation and investment needs in order to provide ample flexibility and to optimize our leverage ratios. See Note 14 for additional information.
Revolving Credit Facility
Our Revolving Credit Agreement contains various covenants, limitations and events of default customary for similar facilities for similarly rated borrowers, including the requirement for us to maintain, at the end of each fiscal quarter, a ratio of net debt to credit adjusted EBITDA in respect of the previous 12-month period. Borrowings under the Revolving Credit Facility are subject to interest at varying spreads above quoted market rates and a commitment fee is paid on the total unused borrowings.
On June 25, 2025, the Company, with its lenders, entered into the Fourth Amended and Restated Credit Agreement (“Revolving Credit Agreement”), which amended and restated the most recent Amendment No. 4 to the Third Amended and Restated Credit Agreement dated September 19, 2023. This amendment and restatement, among other things, extended the termination date to June 25, 2030, as well as removed the financial covenant relief period and associated restrictions.
The Fourth Amended and Restated Credit Agreement states that from the effective date through September 30, 2025, our net debt to credit adjusted EBITDA ratio shall not exceed 4.00x, and shall not exceed 3.75x thereafter, with a temporary step-up to 4.25x permitted for three fiscal quarters following an acquisition exceeding $500 million in paid consideration.
As of September 30, 2026, we had no outstanding borrowings under our $2 billion Revolving Credit Facility. The amount that we are able to draw down under the Revolving Credit Facility is limited by financial covenants as described in more detail below. As of September 30, 2026, our available capacity was $2 billion under the Revolving Credit Facility.
Refer to Note 14 of this Form 10-Q and Part IV, Item 15, “Exhibits and Financial Statement Schedules,” Note 14 of our 2025 Form 10-K for additional information.
Debt Covenants
At September 30, 2026, we were in compliance with all financial and other covenants, including the net debt to credit adjusted EBITDA(1) ratio. At September 30, 2026, our net debt to credit adjusted EBITDA(1) ratio was 2.75 to 1.0 as defined by the credit facility agreements, which is below the relevant level provided by our financial covenants of existing outstanding debt.
(1)Credit adjusted EBITDA and net debt, which are non-GAAP measures used for these covenants, are calculated in accordance with the definition in the debt agreements. In this context, these measures are used solely to provide information on the extent to which we are in compliance with debt covenants and may not be comparable to credit adjusted EBITDA and net debt used by other companies. Reconciliations of credit adjusted EBITDA to net income and of net debt to total debt are as follows:
| (DOLLARS IN MILLIONS) | Twelve Months Ended September 30, 2026 | ||||
| Net income | $ | 183 | |||
| Interest expense | 185 | ||||
| Income taxes | 107 | ||||
| Depreciation and amortization | 851 | ||||
| Specified items(1) | 420 | ||||
| Non-cash items(2) | 357 | ||||
| Credit Adjusted EBITDA**(3)** | $ | 2,103 |
(1)Specified items consisted of restructuring and other charges, impairment of goodwill, divestiture costs, strategic initiative costs, regulatory costs, and other costs that are not related to recurring operations.
(2)Non-cash items consisted of losses (gains) on business disposals, loss on assets classified as held for sale, and stock-based compensation.
(3)Credit Adjusted EBITDA presented includes results from continuing and discontinued operations.
| (DOLLARS IN MILLIONS) | September 30, 2026 | ||||
| Total debt(1) | $ | 6,307 | |||
| Adjustments: | |||||
| Cash and cash equivalents | 519 | ||||
| Net debt | $ | 5,788 |
(1)Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.
Delayed Draw Term Loan Facility
As of September 30, 2026, we had $1.0 billion outstanding under our senior unsecured delayed draw term loan facility. Borrowings bear interest at Term SOFR plus an applicable margin ranging from 0.875% to 1.500% per year, or, at our option, a base rate plus an applicable margin ranging from 0.000% to 0.500% per year, in each case based on our public debt ratings. The loan has a contractual maturity of December 31, 2027, but is subject to mandatory prepayment with the net cash proceeds from the sale of our Food Ingredients business. See Note 14 for additional information.
Senior Notes
As of September 30, 2026, we had $4.697 billion aggregate principal amount outstanding in senior unsecured notes, with the full amount denominated in USD. The notes bear effective interest rates ranging from 1.56% per year to 5.12% per year, with maturities from October 15, 2027 to December 1, 2050. See Note 14 for additional information.
Contractual Obligations
On a total Company basis, we expect to contribute a total of $5 million to our U.S. pension plans and a total of $17 million to our non-U.S. pension plans during 2026. During the nine months ended September 30, 2026, $11 million of contributions were made to the non-U.S. pension plans and $3 million of contributions were made with respect to the non-qualified U.S. pension plans. We also expect to contribute $4 million to our postretirement benefits other than pension plans during 2026. During the nine months ended September 30, 2026, $2 million of benefit payments were made to postretirement benefits other than pension plans.
As discussed in Note 18 to the Consolidated Financial Statements, at September 30, 2026, we had entered into various guarantees and had undrawn outstanding letters of credit from financial institutions. These arrangements reflect ongoing business operations, including commercial commitments, and governmental requirements associated with audits or litigation that are in process with various jurisdictions. Based on the current facts and circumstances, these arrangements are not reasonably likely to have a material impact on our consolidated financial condition, results of operations or cash flows.
New Accounting Standards
Refer to Note 1 to the Consolidated Financial Statements for a discussion of recent accounting pronouncements.
Non-GAAP Financial Measures
We use non-GAAP financial measures in this Form 10-Q, including: (i) comparable currency neutral metrics, (ii) adjusted operating EBITDA, comparable currency neutral adjusted operating EBITDA, (iii) adjusted operating EBITDA margin, and (iv) net debt to credit adjusted EBITDA. We also provide the non-GAAP measure net debt solely for the purpose of providing information on the extent to which the Company is in compliance with debt covenants contained in its debt agreements. Unless otherwise noted, all non-GAAP amounts and percentages in this Form 10-Q reflect the results from continuing operations, with the exception of net debt to credit adjusted EBITDA, which is presented on a combined continuing and discontinued basis. Our non-GAAP financial measures are defined below.
These non-GAAP financial measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculations of such metrics.
Currency Neutral metrics eliminate the effects that result from translating non-U.S. currencies to U.S. dollars. We calculate currency neutral numbers by translating current year invoiced sale amounts at the exchange rates used for the corresponding prior year period. We use currency neutral results in our analysis of segment performance. We also use currency neutral numbers when analyzing our performance against that of our competitors.
Comparable results for the third quarter and first nine months of 2026 exclude the impact of divestitures.
Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization, interest expense, other expense, net, and certain non-recurring or unusual items that are not part of recurring operations such as impairment of goodwill, restructuring and other charges, losses (gains) on business disposals, loss on assets classified as held for sale, divestiture costs, strategic initiative costs, regulatory costs, gain on debt extinguishment, entity realignment costs and other costs that are not related to recurring operations.
Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreements and defined as net debt (which is debt for borrowed money less cash and cash equivalents) divided by the trailing 12-month credit adjusted EBITDA. Credit adjusted EBITDA is defined as income (loss) before interest expense, income taxes, depreciation and amortization, specified items and non-cash items.
Cautionary Statement Under the Private Securities Litigation Reform Act of 1995
This Form 10-Q includes statements that are not historical facts and are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the pending divestiture of the Food Ingredients disposal group and the expected timing and benefits thereof), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management’s present views, are based on a series of expectations, assumptions, estimates and projections about the Company, are subject to change, and involve uncertainties that could cause actual results to differ materially. Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “will”, “would”, “estimate”, “should”, “predict”, “plan”, “project”, “could”, “potential”, “seek”, “target”, “continue”, “future”, and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes. Such risks, uncertainties and other factors include, among others, the following:
-
demand trends, competitive dynamics and customer concentration in our end markets;
-
execution of our strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures;
-
working capital and inventory management;
-
outcomes of legal claims, disputes, regulatory investigations and litigation;
-
tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; volatility in input costs (such as raw materials, transportation and energy);
-
attraction, retention and turnover of key employees and executives; product innovation, time-to-market, product safety and quality;
-
cybersecurity incidents, artificial intelligence compliance risks, data privacy and compliance with data protection laws, and risks associated with the use of artificial intelligence tools;
-
exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks;
-
capital allocation, dividend policy and potential impairments of tangible or intangible assets; our indebtedness, credit rating, liquidity, and access to capital;
-
pension and postretirement obligations;
-
compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices;
-
protection and enforcement of intellectual property;
-
changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and changes in federal, state, local and international rules and regulations.
The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under “Risk Factors” in our 2025 Form 10-K and in our subsequent filings with the SEC, and those disclosures are incorporated herein by reference.
We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this report or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results.
Any public statements or disclosures made by us following this report that modify or impact any of the forward-looking statements contained in or accompanying this report will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this report.
Previous: Item 1. FINANCIAL STATEMENTS. · Next: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.